Rhenium-188 - A Generator-Derived Radioisotope for Cancer Therapy
- 1 January 1998
- journal article
- review article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 13 (5) , 337-349
- https://doi.org/10.1089/cbr.1998.13.337
Abstract
Rhenium-l88 (188Re) is an important therapeutic radioisotope which is obtained on demand as carrier-free sodium perrhenate by saline elution of the tungsten-188/rhenium-188 generator system. With a half-life of 16.9 hours and emission of a high energy beta particle (maximal energy of 2.12 MeV) and a gamma photon (155 keV, 15%) for imaging, 188Re can be provided at reasonable costs for routine preparation of radiopharmaceuticals for cancer treatment.Keywords
This publication has 8 references indexed in Scilit:
- Localization of colorectal carcinoma by rhenium-188-labeled B72.3 antibody in xenografted miceAnnals of Nuclear Medicine, 1998
- Functional Imaging of Hodgkin’s Disease with FDG-PET and Gallium-67Nuklearmedizin-Nuclear Medicine, 1998
- DOTATOC: a powerful new tool for receptor-mediated radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997
- Localization of Small‐cell Lung Cancer Xenografts with Iodine‐125‐, Indium‐111‐, and Rhenium‐188‐Somatostatin AnalogsJapanese Journal of Cancer Research, 1996
- Experimental radiotherapy of receptor‐positive human prostate adenocarcinoma with 188Re‐RC‐160, a directly‐radiolabeled somatostatin analogueInternational Journal of Cancer, 1996
- Preparation and biodistribution of yttrium-90 Lipiodol in rats following hepatic arterial injectionEuropean Journal of Nuclear Medicine and Molecular Imaging, 1995